Prospective identification of patients with chronic lymphocytic leukemia (CLL) destined to progress would greatly facilitate their clinical management. Recently, whole-genome DNA methylation analyses identified three clinicobiologic CLL subgroups with an epigenetic signature related to different normal B-cell counterparts. Here, we developed a clinically applicable method to identify these subgroups and to study their clinical relevance. Using a support vector machine approach, we built a prediction model using five epigenetic biomarkers that was able to classify CLL patients accurately into the three subgroups, namely naive B-cell-like, intermediate and memory B-cell-like CLL. DNA methylation was quantified by highly reproducible bisulfite pyrosequencing assays in two independent CLL series. In the initial series (n = 211), the three subgroups showed differential levels of IGHV (immunoglobulin heavy-chain locus) mutation (P o 0.001) and VH usage (P o 0.03), as well as different clinical features and outcome in terms of time to first treatment (TTT) and overall survival (P o 0.001). A multivariate Cox model showed that epigenetic classification was the strongest predictor of TTT (P o0.001) along with Binet stage (P o0.001). These findings were corroborated in a validation series (n = 97). In this study, we developed a simple and robust method using epigenetic biomarkers to categorize CLLs into three subgroups with different clinicobiologic features and outcome.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease. Some patients remain asymptomatic for a long time, whereas others progress rapidly, have a more aggressive disease and need treatment sooner after diagnosis. 1 In 1999, Damle et al. 2 and Hamblin et al. 3 simultaneously proposed the distinction of two clinicobiologic subtypes of CLL based on the level of somatic mutations in the variable region of the immunoglobulin heavychain locus (IGHV). Those CLL patients whose tumor cells bear high levels of IGHV somatic mutation (mutated CLL) are associated with a favorable clinical course, whereas those CLLs with no or low level of IGHV somatic mutation (unmutated CLLs) have an adverse outcome. The differential IGHV mutational load in these two groups suggests that they originate from CD5+ B cells at different maturation stages (pregerminal center in unmutated CLLs and postgerminal center B cell in mutated CLLs), 3, 4 as further supported by recent transcriptional and epigenetic data. 5, 6 Several surrogate markers of the IGHV mutational status have been identified and used in the clinical practice, such as ZAP-70, whose high expression has been associated with unmutated CLL and poor prognosis. 7 In addition to the IGHV mutational status, cytogenetic alterations and, more recently, gene mutations have also been associated with the clinical behavior of patients with CLL. [8] [9] [10] [11] [12] [13] Alterations in the DNA methylation pattern represent one of the major molecular hallmarks of cancer cells, 14, 15 and several epigenetic biomarkers are currently used in the clinical setting. 16 Furthermore, DNA methylation is not only related to cancerassociated gene deregulation but also this epigenetic mark has been linked with cell identity and cellular memory of activity states. 17, 18 Therefore, DNA methylation may be used to track the cellular origin of different lymphoid neoplasms. In a wholegenome analysis of the DNA methylome of CLL, we found that mutated CLL and unmutated CLL maintain an epigenetic signature of memory B cells and naive B cells, respectively. 5 Recently, using an extensive DNA methylation signature associated with normal B-cell differentiation, we suggested the presence of three subgroups of CLL with different clinicobiologic features. 5 We postulated that DNA methylation patterns associated with normal B cells could be used to classify CLLs into three novel subgroups. To test this hypothesis and to develop a clinically applicable strategy, we identified five epigenetic biomarkers with high classification power, established new quantitative DNA methylation assays and applied them to two independent series of CLL patients of different geographical origin.
MATERIALS AND METHODS

Identification of epigenetic biomarkers
We have previously reported a DNA methylation signature of 1649 CpGs that categorized CLL cases into three epigenetic subgroups related to different B-cell differentiation stages, that is, naive B-cell-like CLL (n-CLL), memory B-cell-like CLL (m-CLL) and intermediate CLL (i-CLL). 5 To reduce the number of CpGs necessary to define each subgroup, we compared DNA methylation levels (transforming β-values into M-values) 19 between n-CLLs and i-CLLs vs m-CLLs as well as i-CLLs and m-CLLs vs n-CLLs using the limma package (R software) and we established a ranking of CpGs based on their adjusted P-value. Given that i-CLLs have an intermediate DNA methylation pattern between n-CLLs and m-CLLs, we also compared i-CLLs vs m-CLLs, and i-CLLs vs n-CLLs. From each comparison, we selected the top five CpGs of each list. Out of the resulting 16 unique CpGs, we fitted a support vector machine (SVM) model for each of the CpGs combinations, and estimated its error rate using a.632+ bootstrap strategy with 1000 replicates. 20, 21 The selected combination of five CpGs showed a good compromise between the number of variables and the error rate, which was only 1%. For the fitted SVM models, we used a radial basis kernel, and the same boostrap strategy was used to optimize the regularization parameter C the γ parameter of the kernel function. Subsequently, we built an SVM model using five CpGs to classify samples into each of the epigenetic CLL subgroups (Supplementary Methods).
DNA methylation studies
To simplify the assessment of the epigenetic origin of CLLs, we performed bisulfite pyrosequencing (BPS) assays of purified CLL B cells (AutoMACS; Miltenyi Biotec, Bergisch Gladbach, Germany) with the PyroMark Q96 ID sequencer (Qiagen, Hilden, Germany), as previously described, 22, 23 using specific primers (Supplementary Methods and Supplementary Table S1 ). The median tumor cell purity in the initial and validation series was 96% (range, 62-100%). DNA methylation levels were quantified with the PyroMark CpG software (Qiagen) and compared by bivariate correlation analysis with the values obtained in the array (Pearson's correlation coefficient). The epigenetic subgroup was assigned based on the BPS results using the SVM prediction model (Supplementary Methods and Supplementary Figure S1 ). To test the reproducibility of the assays and prediction algorithm, BPS of 19 CLLs was performed in two independent laboratories.
Patients
The epigenetic classification that derived from the simplified BPS analysis was first determined in an initial cohort of 211 CLL patients, which comprised 84 women and 127 men with a median age of 61 years (range, . These cases are included in the CLL genome project of the International Cancer Genome Consortium. In addition, an independent validation series of 97 CLL patients comprised of 31 women and 66 men with a median age of 65 years (range, 33-91) from an independent Institution (University of Leicester, Leicester, UK) was studied. All the patients were untreated at time of BPS determination. The main clinicobiologic features, treatment and outcome of the two series are detailed in Supplementary Methods and Supplementary Table S2 . Standard criteria for starting treatment were used. [24] [25] [26] To test the stability of the epigenetic biomarkers over time and after treatment, we analyzed two or three sequential samples of 27 CLL patients with a median sampling difference between samples of 59 months (range, 5-114). In 13 patient samples, pre-and posttreatment were analyzed. All subjects gave informed consent for their participation according to the local Ethic Committees and/or International Cancer Genome Consortium guidelines.
Further statistical analyses
The relationship between the epigenetic classification of the CLL and the clinical and biologic variables of the patients was evaluated using Fisher's or nonparametric tests. Time to first treatment (TTT) and overall survival (OS) were calculated using the Kaplan-Meier estimator 27 and the univariate comparison by means of the log-rank test. 28 Potential prognostic factors for both end points were evaluated in multivariate analyses using Cox proportional hazard regression. 29, 30 Details of the multivariate analysis and c-statistics and prediction error curves/integrated Brier scores are described in the Supplementary Methods. The influence of epigenetic subgroup on the cumulative incidence of transformation to diffuse large B-cell lymphoma (DLBCL) was analyzed by taking death as a competing risk.
RESULTS
Epigenetic biomarkers and development of a simplified quantitative assay
As the epigenetic signature of 1649 CpG sites identified in our previous study 5 was largely redundant (Figure 1a ), we aimed at identifying a small set of epigenetic biomarkers allowing us to classify CLL patients with similar accuracy. After performing various comparisons of microarray-based DNA methylation data transformed to M-values, 5, 19 we identified a set of five CpG sites that classified 132/133 of the patients into the right epigenetic subgroup (Figure 1b and Supplementary Figure S1 ). These five regions were located in the promoter region of SCARF1 (cg00869668), in the gene body of B3GNTL1 (cg11472422), CTBP2 (cg17014214) and TNF (cg09637172), and in a chromosome 14 intergenic region (cg03462096) ( Table 1 ). After this step of complexity reduction, we developed cost-effective BPS assays to quantify the DNA methylation levels of these CpG sites ( Supplementary Table S1 ). The accuracy of the new assays was tested comparing microarray and BPS methylation values in 15 CLL cases of each epigenetic subgroup, and the results were highly comparable (average Pearson's coefficient of 0.987, P o 0.001 for each CpG site; Figure 1c ). The SVM-based prediction model using BPS data allowed the correct classification of all these 45 cases to their corresponding epigenetic CLL subgroup.
Moreover, we tested the interlaboratory reproducibility of the new BPS assays and epigenetic prediction model. A total of 19 CLL samples were blindly processed into two different laboratories (Barcelona and Kiel), including cell separation from different aliquots of the same tumor sample, DNA isolation and BPS. We observed that the DNA methylation levels derived from the five CpGs and the epigenetic classification of the cases as n-CLL, m-CLL or i-CLL using the SVM prediction model were highly reproducible between both institutions (Pearson's correlation coefficient of 0.976, and weighted Cohen's κ-coefficient of 0.96, P o 0.001, respectively; Supplementary Figure S2 ).
Additionally, a prerequisite to evaluate the clinical impact of the epigenetic classification based on these five biomarkers is that the DNA methylation levels remain stable over time and are not influenced by treatment. To analyze this aspect, we selected samples from 27 CLL patients obtained at two or three different time points, including 13 pre-and posttreatment samples. We observed that DNA methylation values of the five CpG sites in the sequential samples were highly concordant (Pearson's correlation coefficient of 0.984, 95% confidence interval (CI): 0.953-1.0). This finding confirms that the DNA methylation levels of the five biomarkers and the epigenetic subgroup remains stable during the course of the disease (Supplementary Figure S3 ), allowing to use clinical data from the time of diagnosis in further statistical analyses.
Clinicobiologic features of CLL based on the epigenetic classification Once we confirmed the accuracy and reproducibility of our simplified epigenetic assay and prediction model, we applied the analysis to the initial series of 211 patients and classified 90 cases (43%) as n-CLL, 23 (11%) as i-CLL and 98 (46%) as m-CLL (Figure 2a ). The clinicobiologic features of the CLL epigenetic subgroups are listed in Table 2 . The percentage of cases with unmutated IGHV was 97% for n-CLL, 22% for i-CLL and 5% for m-CLL (P o 0.001). Moreover, the levels of IGHV somatic mutation in these epigenetic subgroups were clearly different, that is, the mean percentage of identity to IGHV germline was 99.7% for n-CLL, 96.4% for i-CLL and 92.9% for m-CLL (Po 0.001; Figure 2c ). Analyzing the VH usage of each subgroup, we observed that the most frequent rearrangements were VH1-69 in n-CLL (27%; Po 0.001), VH4-34 in m-CLL (19%; P = 0.001) and VH3-23 (17%; P = 0.02) and VH1-18 (13%; P = 0.02) in i-CLL (Table 2 ). NOTCH1 mutations were mainly observed in the n-CLL subgroup, whereas SF3B1 mutations were more frequently observed in i-CLL. We detected significant differences in Binet and Rai stages at diagnosis, with early stages more frequently seen in m-CLL.
Although our findings suggest that n-CLL, i-CLL and m-CLL represent different subgroups of the disease, we further investigated the specific features of the i-CLL cases. This subgroup contained cases showing a unimodal distribution of moderately mutated IGHV (Figure 2c and Supplementary Figure S4a ), particular VH usage (13% VH1-18 vs 2% in n-CLL and m-CLL, P = 0.006), as well as a higher incidence of SF3B1 mutations (22% vs 6% in n-CLL and m-CLL, P = 0.01). Collectively, these data suggest that the i-CLL subgroup represents a distinct clinicobiologic CLL subgroup rather than a mere mixture of n-CLL and m-CLL cases.
Surviving patients had a median follow-up of 7.9 years (range, 0.4-24), with 103 patients (49%) eventually requiring treatment. Median TTT for n-CLL, i-CLL and m-CLL patients in Binet stages A and B was 3.1 years, 12.3 years and non-reached, respectively (P o 0.001; Figure 3a ). Other variables predicting shorter TTT were unmutated IGHV, high ZAP-70, high CD38, mutated NOTCH1, mutated SF3B1, elevated LDH, elevated β 2 -microglobulin and adverse cytogenetics (del(11q) and/or del(17p)) (P ⩽ 0.02 for each comparison). A multivariate Cox analysis demonstrated the independent value of the epigenetic classification to predict TTT (Supplementary Result and Table S3 ). Treatment given to the patients did not significantly differ among the epigenetic subgroups. Thirty-seven patients died during the follow-up, with a 10-year OS of 52%, 96% and 93% for n-CLL, i-CLL and m-CLL, respectively (P o 0.001; Figure 3b ). Other variables predicting shorter OS were age ⩾ 70 years, unmutated IGHV, high CD38, high ZAP-70, advanced Rai or Binet stages, adverse cytogenetics, mutated SF3B1, elevated LDH and elevated β 2 -microglobulin (P ⩽ 0.01 for each comparison). In the multivariate analysis, only IGHV mutational status, age and Binet stage retained independent prognostic significance to predict OS (Supplementary Result and Table S3 ). Finally, 12 CLL patients developed transformation to DLBCL, with a 10-year risk of cumulative incidence of Five CpG sites whose methylation levels are able to classify CLL patients accurately as the initial 1649 CpG signature. Asterisk refers to one case that was classified as n-CLL with the 1649 CpG signature and as i-CLL with the 5 CpG signature. (c) DNA methylation levels of the five CpG sites quantified by the novel BPS assays highly correlate with those detected by 450k microarrays. In general, the shown heatmaps are graphical representations of data matrices without applying any clustering method (with the exception of rows of panel a, which were clustered using average linkage and Manhattan distance measure). transformation of 18%, 7% and 0% for n-CLL, i-CLL and m-CLL, respectively (P o0.001).
Validation of the epigenetic classification in an independent series
The clinicobiologic characteristics and the prognostic value of the epigenetic classification were assessed in an independent validation series of 97 CLL patients from a different geographical origin. We applied the simplified BPS analysis and SVM prediction model to this validation series and classified 35 cases (36%) as n-CLL, 15 (15%) as i-CLL and 47 (48%) as m-CLL ( Figure 2b ). As shown in Supplementary Table S4 , the great majority of the clinicobiologic features of the epigenetic subgroups observed in the initial series were confirmed in this second series. Among those, we observed an identical distribution of IGHV mutational levels, with a mean identity to germline of 99.3% in n-CLLs, 96.4% in i-CLLs and 93.4% in m-CLLs (P o0.001; Figure 2c and Supplementary Figure S4b ). In addition, a similar impact of the The distribution of the levels of IGHV somatic hypermutation is different in the three groups both in the initial (left) and validation (right) series (upper panels). This distribution is mostly unimodal in all three CLL subgroups (lower panels). In particular, the i-CLL subgroup is not made out of m-CLL and n-CLLs, but rather represents a group with cases bearing a moderate level of somatic mutation. Heatmaps are graphical representations of data matrices without applying any clustering method. epigenetic classification was observed on TTT (10-year TTT of 93% vs 61% vs 18% for n-CLL, i-CLL and m-CLL, respectively; P o 0.001; Figure 3c ) and on OS (10-year OS of 28% vs 70% vs 79% for n-CLL, i-CLL and m-CLL, respectively; P o 0.001; Figure 3d ). The independent prognostic impact of the epigenetic subgroups to predict TTT was also validated in the Cox multivariate analysis ( Supplementary Table S5 ).
Epigenetic classification as the strongest independent prognostic factor for TTT in CLL After validating the clinicobiologic significance of the epigenetic classification in two independent and geographically different CLL series, we merged them to gain statistical power to define the main features predicting TTT and OS of the patients. Kaplan-Meier plots of TTT and OS for the complete series showed that the epigenetic classification has a major impact on CLL prognosis (Figures 3e and f) . Additionally, we performed a Cox multivariate analysis including the following variables: gender, age, Binet stage, epigenetic classification, IGHV mutational status, adverse cytogenetic alterations, NOTCH1 mutations and SF3B1 mutations, as well as CD38, ZAP-70, serum LDH and β2-microglobulin values.
The final model showed that the epigenetic signature related to the cellular origin of CLL was the most important variable to predict TTT, together with Binet stage, CD38 expression, LDH levels and SF3B1 mutations (Table 3 ). Furthermore, the relative power of epigenetics in comparison with IGHV was validated with the c-statistics method (Supplementary Information and Supplementary Table S6 ).
DISCUSSION
We have developed a clinically applicable strategy to track the cellular origin of CLL based on five epigenetic biomarkers, and identified three CLL subgroups. These CLL subgroups have distinct IGHV mutational load, different VH usage and varying proportions of somatic mutations in NOTCH1 and SF3B1. This new categorization of patients also has a major clinical impact confirmed in the two independent series of different geographical origin. During the past decades, the great majority of the epigenetic studies have focused on cancer-specific gene deregulation by DNA methylation, 31, 32 although available data also suggest that the tissue-of-origin signature also allows an accurate classification of tumor types. 33 In CLL, whose cellular origin has been extensively debated, 4, 6, 34 we recently observed that an epigenetic signature related to normal B-cell differentiation was able to classify CLLs into three novel subgroups. 5 Out of an extensive DNA methylation signature, we extracted five biomarkers with high classification power and developed assays with high interlaboratory reproducibility. The methylation levels of these five CpGs belonging to B3GNTL1, CTBP2, SCARF1, TNF and an intergenic region are modulated during B-cell differentiation, where they seem to act as enhancers (Table 1 ). In CLL, the varying methylation levels of these biomarkers are not translated into gene expression changes (Supplementary Figure S5 ), suggesting that they may not have a functional impact but represent a stable molecular mark of the cellular origin of each CLL subgroup.
The n-CLL subgroup has an epigenetic signature of pregerminal center B cells and m-CLL of postgerminal center B cells. (Table 3 ). Cox proportional hazard regression analysis performed in 295 patients in Binet stage A or B collected from initial and validation series.
These two subgroups show a major overlap with unmutated CLL and mutated CLL, respectively. An interesting finding of our studies is the identification of i-CLLs as a third subgroup of CLLs. Based on the IGHV mutational status, both i-CLLs and m-CLLs would be classified as mutated CLLs, although the former shows a worse clinical behavior. Such i-CLLs comprise about 15% of all cases and do not seem to be a mere gray zone between m-CLL and n-CLL, but a distinct subgroup with a differential putative cellular origin and clinicobiologic characteristics. Although the cellular origin of i-CLL still remains to be identified, we postulate that it may be derived from a germinal center-independent marginal zone B cell. Similar to i-CLLs, this B-cell subtype shows moderate levels of somatic IGHV mutation and elevated frequency of VH3-23 rearrangements. 35, 36 In terms of oncogenic alterations, i-CLLs show a significant increase of SF3B1 mutations. Although recent findings also identify high frequencies of SF3B1 mutations in poor prognostic stereotyped CLLs, 37 we did not observe an overlap between this group of CLLs and i-CLLs. The IGHV mutational status has been, for the past two decades, the most relevant biologic feature to classify CLL and to predict the clinical behavior of the patients. 38 The categorization of CLL patients both according to the IGHV mutational status and the epigenetic subgroups seems to reflect the cellular origin. Not surprisingly, there is a close association between these two classification strategies as reflected by the fact that 95% of m-CLLs belong to mutated CLL, and 97% of n-CLLs correspond to unmutated CLL. This is most likely the reason why IGHV and epigenetics are mutually exclusive in the multivariate studies. Thus, we observed that epigenetics is the strongest predictor for TTT, among other well-known prognostic factors (Table 3) , overcoming the role of IGHV. TTT is probably the best end point in historical CLL series, reflecting the aggressiveness of the disease. Whereas therapeutic armamentarium has changed in the past decades resulting in better OS, 39 the criteria to start treatment have basically remained unmodified. [24] [25] [26] Based on our findings, the three epigenetic subgroups seem to predict prognosis in CLL in a more accurate manner than the two subgroups based on IGHV mutational status. Nevertheless, we believe that the most relevant information obtained by the five epigenetic biomarkers is to classify CLL patients based on the putative cell of origin of the disease rather than being a mere additional prognostic biomarker. The recent advance in the genetics and cellular biology of CLL, including the present epigenetic classification, could result in the use of targeted therapies for specific subgroups of patients.
In conclusion, we have established a simplified and reproducible method to track the cellular origin of CLL applying epigenetic biomarkers. Using this strategy, CLL patients can be categorized into three epigenetic subgroups with differential clinicobiologic features and outcome. Abbreviations: 95% CI, 95% confidence interval; ESG, epigenetic subgroup; LDH, lactate dehydrogenase. Codification of categorical variable ESG: ESG (1)-n-CLL = 1, i-CLL = 0, m-CLL = 0; ESG (2)-n-CLL = 0, i-CLL = 1, m-CLL = 0.
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